NYSE:PFE
Pfizer Inc.
- Stock
$
Who are the key people at Pfizer?
William Pao, David Denton, Angela Hwang, Albert Bourla, and the people working on Pfizer's injectable and hospital products.
What is Pfizers business model?
Pfizer's business model is to sell Covid shots and other pharmaceutical products.
What does Pfizer do?
Pfizer manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal, as well as opthalmology and antiparasitic. The company also provides multivitamins, vitamins/minerals, antibiotics, steroids, and vaccines. It sells its products through a network of independent distributors primarily under various brand names.
How does Pfizer earn money?
Pfizer earns money by manufacturing, marketing, trading in, and exporting pharmaceutical products in India and internationally. It also earns money from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill, as well as from multivitamins, vitamins/minerals, antibiotics, steroids, and vaccines. In the third quarter of 2022, the company brought in $8.6 billion in net income on $22.6 billion in revenue. Pfizer is also looking to focus on vaccines and developing new medicines to maximize value for shareholders.
What are risks in investing in Pfizer?
Pfizer is expected to face the loss of patents for some key drugs between 2025 and 2030, and the company's stock has already fallen 25% in 2022 on fears that its post-Covid growth story may not continue. Additionally, the megadeals that Pfizer executives have long used to turbo-charge growth have gotten more expensive and more difficult to complete, with interest rates rising and antitrust fervor in Washington.
What could be reasons to buy Pfizer stock?
Despite the stock falling 15% in 2023, investors may still find reasons to buy Pfizer stock. Pfizer has recently made several acquisitions, including Biohaven Pharmaceutical, Arena Pharmaceuticals and Global Blood Therapeutics, which have added several cancer and inflammatory disease drugs to its pipeline. Additionally, Pfizer has a vaccine for respiratory syncytial virus (RSV) in its pipeline and is expected to submit data supporting authorization of a three-dose regimen of the Covid-19 vaccine for children under the age of 5 to U.S. regulators by early June. Pfizer also has a strong balance sheet and is likely to use its resources for dividends and share buybacks or on deals to bring in new drugs.
What could be reasons to sell Pfizer stock?
Investors may be selling Pfizer stock due to the company's projected decline in Covid-19 related sales to about $21.5 billion in 2023, down sharply from $56.7 billion last year. Additionally, the stock has slumped 15% this month, erasing $43 billion in market value, and is down by about 15% this year, the worst performance among large-cap pharmaceuticals. Furthermore, Pfizer needs to spend more money on research development and on commercial launches this year to grow its non-Covid business, which could lead to a decrease in profitability.
Is Pfizer profitable?
Yes, Pfizer is profitable. In 2022, the company brought in $8.6 billion in net income on $22.6 billion in revenue. Pfizer's total annual sales crossed the $100 billion-mark for the first time in 2022, driven by the more than $56 billion in sales of the COVID-19 vaccine and Paxlovid antiviral. The company is also looking to focus on vaccines and developing new medicines to maximize value for shareholders.
Are there any recent scandals involving Pfizer ?
No, there are no recent scandals involving Pfizer. The news paragraphs from 2023-01-31 indicate that Pfizer has completed a series of acquisitions over the past few years in order to gain access to promising new medications. Additionally, the company is preparing for a wave of launches resulting from its current research and development work as many as 19 over the next 18 months, according to a spokesperson. There is no indication of any legal or moral issues involving Pfizer.
What are most important products and service that Pfizer is selling?
Pfizer is selling a wide range of pharmaceutical products and services, including vaccines, antivirals, multivitamins, vitamins/minerals, antibiotics, steroids, and other therapeutic products in areas such as anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal. Additionally, Pfizer has recently expanded its not-for-profit pledge to include more medicines and is collaborating with the U.S. government to supply its COVID-19 vaccine to lower-income countries. The company is also preparing for a wave of launches resulting from its current research and development work as many as 19 over the next 18 months.
Is Pfizer known for tax avoidance?
No, Pfizer is not known for tax avoidance. The company has been the subject of an investigation by Italy's financial police alleging that it hid at least 1.2 billion euros ($1.2 billion) in profit by transferring money to units in other countries, according to people familiar with the investigation. However, Pfizer has stated that it complies with the tax laws and requirements of Italy and cooperates with audits and investigations.
Is Pfizer have a broad or narrow customer base?
Pfizer has a broad customer base, as it offers its products in various therapeutic areas and sells its products through a network of independent distributors.
Is Pfizer dependent on subsidies?
No, Pfizer is not dependent on subsidies. The company has recently expanded its not-for-profit pledge to include more medicines, and has received federal support such as a $1.95 billion advance-purchase agreement via the government's Operation Warp Speed. However, Pfizer has also recently announced a 400% price hike on its COVID-19 vaccines, which will be picked up by health insurers, potentially leading to higher premiums.
Are people in Pfizers management involved in legal or moral issues?
No, there is no indication that people in Pfizers management are currently involved in any legal or moral issues. The news paragraphs from 2022-10-26 indicate that Pfizer Inc. is the target of an Italian probe alleging the company hid at least 1.2 billion euros ($1.2 billion) in profit by transferring money to units in other countries. However, there is no indication that people in Pfizers management are involved in this legal issue.
Is Pfizer a market leader?
Yes, Pfizer is a market leader in the pharmaceutical industry. The company has been dominating the $7 billion worldwide market for pneumonia vaccines for more than a decade and is forecast to reach more than $10 billion annually by 2028, according to Wall Street analysts. Additionally, Pfizer's Comirnaty vaccine brought in more than $36 billion in sales globally last year, and analysts expect it to bring in nearly $33 billion this year. Furthermore, Pfizer is also collaborating with the U.S. government to supply its COVID-19 vaccine to lower-income countries.
Does Pfizer have legal issues?
Yes, Pfizer is currently the target of an Italian probe alleging the company hid at least 1.2 billion euros ($1.2 billion) in profit by transferring money to units in other countries. Additionally, Moderna has filed patent infringement lawsuits against Pfizer and BioNTech in both U.S. federal court and a German court, and GSK has brought indemnification claims against Pfizer in relation to potential Zantac liabilities.
Was Pfizer involved in human rights violations?
No, there is no evidence that Pfizer has been involved in any human rights violations. The news context provided does not mention any legal or moral issues related to the company.
Is Pfizer a green business?
No, Pfizer is not a green business. The company manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, such as anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal, as well as opthalmology and antiparasitic. The company also provides multivitamins, vitamins/minerals, antibiotics, steroids, and vaccines. It does not offer any green products or services.
What are key components of Pfizer supply chain?
The key components of Pfizer's supply chain are training, education, and support on supply-chain issues; collaboration with the U.S. government to supply their COVID-19 vaccine to a bigger pool of lower-income countries; proactive investment in European manufacturing; and working with Project Last Mile to help deliver drugs and other medical supplies.
Is Pfizer growing in its industry?
Yes, Pfizer is growing in its industry. In 2022, the company generated nearly $57 billion in combined sales from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill, which accounted for almost 60% of the company's total revenue for the year. Pfizer is also investing more than $2.5 billion to expand its European manufacturing capabilities and is preparing for a wave of launches resulting from its current research and development work, with as many as 19 launches expected over the next 18 months. Additionally, the company is looking to focus on vaccines and developing new medicines to maximize value for shareholders.
Is Pfizer a mature company?
No, Pfizer is not a mature company. Despite the success of its Covid-19 vaccine and antiviral pill, the company is continuing to invest in research and development and is preparing for a wave of launches resulting from its current work. Additionally, Pfizer is looking to focus on vaccines and developing new medicines to maximize value for shareholders. This indicates that the company is still growing and expanding its operations, rather than being in a mature state.
Does Pfizer have a sustainable competitive advantage?
Yes, Pfizer has a sustainable competitive advantage. The company is continuing to invest in its research and development capabilities, with plans to launch as many as 19 products over the next 18 months. Additionally, Pfizer has a strong presence in the COVID-19 vaccine and antiviral drug markets, which are expected to remain multibillion dollar revenue generators for years to come. Furthermore, Pfizer is also investing in other therapeutic areas such as anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal. This diversification of products and services gives Pfizer a competitive edge over its competitors.
How is the current situtation around Pfizer?
Pfizer is currently in a strong position, with blockbuster sales from its COVID-19 vaccine and antiviral drug, as well as plans to launch as many as 19 products over the next 18 months. The company is also investing in other therapeutic areas such as anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal. This diversification of products and services gives Pfizer a competitive edge over its competitors. Additionally, Pfizer is also preparing for a wave of launches resulting from its current research and development work and is expected to generate $56 billion in sales this year from its two top products.
What challenges does Pfizer face?
Pfizer faces a number of challenges, including the potential impact of public health outbreaks, epidemics and pandemics, such as the ongoing COVID-19 pandemic, as well as operational or financial difficulties associated with its reliance on agreements with Pfizer in connection with the Combination. Additionally, Pfizer is facing rising interest rates and increased antitrust fervor in Washington, which could make it more difficult and expensive to complete megadeals that have been used to turbo-charge growth in the past. Furthermore, Pfizer is also facing competition from generics for some of its current mainstays.
Is the core business of Pfizer healthy?
Yes, the core business of Pfizer is healthy. The company has recently expanded its not-for-profit pledge to include more medicines, and is expecting to launch as many as 19 products over the next 18 months. Additionally, Pfizer has a strong presence in the COVID-19 vaccine and antiviral drug markets, which are expected to remain multibillion dollar revenue generators for years to come. Furthermore, Pfizer is investing in other therapeutic areas such as anti-allergic, anti-diabetic, antihistamine, anti-infective, anti-parasitic, cardiovascular, dermatology, erectile dysfunction, neurology, pain/fever/inflammation, pediatrics, psychiatry, respiratory, urology, women's health, central nervous system, autoimmune disorders, and gastrointestinal. This diversification of products and services gives Pfizer a competitive edge over its competitors.
What are the main competitors of Pfizer?
Pfizer is facing competition from generics for some of its current mainstays, as well as from rival drugmakers who are seeking to upend Pfizer's dominance of the $7 billion worldwide market for pneumonia vaccines. Merck Co. has already introduced a new competitor to Pfizers Prevnar vaccine franchise, while GSK PLC and Vaxcyte Inc. are among companies developing shots that aim to win sales by protecting against even more strains of the pneumonia virus.